Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa.
Aker BioMarine Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr44.25|
|52 Week High||kr39.70|
|52 Week Low||kr129.08|
|1 Month Change||-12.03%|
|3 Month Change||-42.75%|
|1 Year Change||-52.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-57.74%|
Recent News & Updates
|AKBM||NO Food||NO Market|
Return vs Industry: AKBM underperformed the Norwegian Food industry which returned 14.3% over the past year.
Return vs Market: AKBM underperformed the Norwegian Market which returned 22.8% over the past year.
Stable Share Price: AKBM is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AKBM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates in two segments, Ingredients and Brands. The company provides krill oil products, including omega-3s, phospholipids, choline, and astaxanthin under the Superba, Kori, NKO, and K·REAL brands.
Aker BioMarine Fundamentals Summary
|AKBM fundamental statistics|
Is AKBM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AKBM income statement (TTM)|
|Cost of Revenue||US$160.52m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 29, 2021
|Earnings per share (EPS)||-0.093|
|Net Profit Margin||-2.87%|
How did AKBM perform over the long term?See historical performance and comparison
Is Aker BioMarine undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AKBM (NOK44.25) is trading below our estimate of fair value (NOK342.88)
Significantly Below Fair Value: AKBM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AKBM is unprofitable, so we can't compare its PE Ratio to the Norwegian Food industry average.
PE vs Market: AKBM is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKBM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKBM is good value based on its PB Ratio (1.2x) compared to the NO Food industry average (2.5x).
How is Aker BioMarine forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKBM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: AKBM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AKBM's is expected to become profitable in the next 3 years.
Revenue vs Market: AKBM's revenue (13.4% per year) is forecast to grow faster than the Norwegian market (5.7% per year).
High Growth Revenue: AKBM's revenue (13.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AKBM's Return on Equity is forecast to be low in 3 years time (7.2%).
How has Aker BioMarine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKBM is currently unprofitable.
Growing Profit Margin: AKBM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AKBM is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare AKBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKBM is unprofitable, making it difficult to compare its past year earnings growth to the Food industry (33.1%).
Return on Equity
High ROE: AKBM has a negative Return on Equity (-2.11%), as it is currently unprofitable.
How is Aker BioMarine's financial position?
Financial Position Analysis
Short Term Liabilities: AKBM's short term assets ($247.3M) exceed its short term liabilities ($77.3M).
Long Term Liabilities: AKBM's short term assets ($247.3M) do not cover its long term liabilities ($325.2M).
Debt to Equity History and Analysis
Debt Level: AKBM's debt to equity ratio (84.4%) is considered high.
Reducing Debt: AKBM's debt to equity ratio has reduced from 215.9% to 84.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKBM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AKBM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aker BioMarine current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKBM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKBM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKBM's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matts Johansen (45 yo)
Mr. Matts Johansen has been Chief Executive Officer at Aker BioMarine ASA since July 1, 2015. Mr. Johansen has been Chief Operating Officer of Aker Biomarine Antarctic AS since June 1, 2012. He serves as P...
CEO Compensation Analysis
Compensation vs Market: Matts's total compensation ($USD630.00K) is about average for companies of similar size in the Norwegian market ($USD616.98K).
Compensation vs Earnings: Matts's compensation has been consistent with company performance over the past year.
Experienced Management: AKBM's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: AKBM's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AKBM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Aker BioMarine AS's employee growth, exchange listings and data sources
- Name: Aker BioMarine AS
- Ticker: AKBM
- Exchange: OB
- Founded: NaN
- Industry: Packaged Foods and Meats
- Sector: Food, Beverage & Tobacco
- Market Cap: kr3.876b
- Shares outstanding: 87.59m
- Website: https://www.akerbiomarine.com
Number of Employees
- Aker BioMarine AS
- Oksenøyveien 10
- PO Box 496
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 21:37|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.